These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20067332)

  • 1. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.
    Bridges JF; Onukwugha E; Mullins CD
    Pharmacoeconomics; 2010; 28(3):175-84. PubMed ID: 20067332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf.
    Siverskog J; Henriksson M
    Med Decis Making; 2020 Apr; 40(3):399-403. PubMed ID: 32172657
    [No Abstract]   [Full Text] [Related]  

  • 3. Determinants of Change in the Cost-effectiveness Threshold.
    Paulden M; O'Mahony J; McCabe C
    Med Decis Making; 2017 Feb; 37(2):264-276. PubMed ID: 27553208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres L; García-Lorenzo B; Castilla I; Valcárcel-Nazco C; García-Pérez L; Linertová R; Polentinos-Castro E; Serrano-Aguilar P
    Value Health; 2016; 19(5):558-66. PubMed ID: 27565273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informing a cost-effectiveness threshold for Saudi Arabia.
    Al-Jedai AH; Lomas J; Almudaiheem HY; Al-Ruthia YSH; Alghamdi S; Awad N; Alghamdi A; Alowairdhi MA; Alabdulkarim H; Almadi M; Bunyan RF; Ochalek J
    J Med Econ; 2023; 26(1):128-138. PubMed ID: 36576804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inquiry into the relationship between equity weights and the value of the QALY.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2012 Dec; 15(8):1119-26. PubMed ID: 23244815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the $50,000 per QALY Threshold.
    Nwachukwu BU; Bozic KJ
    J Arthroplasty; 2015 Jul; 30(7):1118-20. PubMed ID: 25737385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QALYs, standard gambles, and the expected budget constraint.
    Blomqvist A
    J Health Econ; 2002 Mar; 21(2):181-95. PubMed ID: 11939237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling Healthcare Costs: Just Cost Effectiveness or "Just" Cost Effectiveness?
    Fleck LM
    Camb Q Healthc Ethics; 2018 Apr; 27(2):271-283. PubMed ID: 29509125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management.
    Schultz BG; Tilton J; Jun J; Scott-Horton T; Quach D; Touchette DR
    Value Health; 2021 Apr; 24(4):522-529. PubMed ID: 33840430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.